{"pmid":32278879,"title":"Testing for COVID-19 in lung cancer patients.","text":["Testing for COVID-19 in lung cancer patients.","Ann Oncol","Passaro, Antonio","Peters, Solange","Mok, Tony S K","Attili, Ilaria","Mitsudomi, Tetsuya","de Marinis, Filippo","32278879"],"journal":"Ann Oncol","authors":["Passaro, Antonio","Peters, Solange","Mok, Tony S K","Attili, Ilaria","Mitsudomi, Tetsuya","de Marinis, Filippo"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278879","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.annonc.2020.04.002","keywords":["COVID-19","lung cancer"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663890922000089088,"score":7.9164424,"similar":[{"pmid":32278368,"title":"Challenges in lung cancer therapy during the COVID-19 pandemic.","text":["Challenges in lung cancer therapy during the COVID-19 pandemic.","Lancet Respir Med","Calabro, Luana","Peters, Solange","Soria, Jean-Charles","Di Giacomo, Anna Maria","Barlesi, Fabrice","Covre, Alessia","Altomonte, Maresa","Vegni, Virginia","Gridelli, Cesare","Reck, Martin","Rizvi, Naiyer","Maio, Michele","32278368"],"journal":"Lancet Respir Med","authors":["Calabro, Luana","Peters, Solange","Soria, Jean-Charles","Di Giacomo, Anna Maria","Barlesi, Fabrice","Covre, Alessia","Altomonte, Maresa","Vegni, Virginia","Gridelli, Cesare","Reck, Martin","Rizvi, Naiyer","Maio, Michele"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278368","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S2213-2600(20)30170-3","source":"PubMed","topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1663890921975971840,"score":57.522034},{"pmid":32118394,"title":"[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].","text":["[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].","With the increasing number of cases and widening geographical spread, the 2019 novel coronavirus disease (COVID-19) has been classified as one of the class B infectious diseases but prevented and controlled as class A infectious disease by the National Health Commission of China. The diagnosis and treatment of lung cancer patients have been challenged greatly because of extraordinary public health measures since the lung cancer patients are a high-risk population during the COVID-19 outbreak period. Strict protection for lung cancer patients is needed to avoid infection. Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients. This review will demonstrate how to applicate appropriate and individual management for lung cancer patients to protect them from COVID-19.","Zhonghua Zhong Liu Za Zhi","Yang, L","Xu, H Y","Wang, Y","32118394"],"abstract":["With the increasing number of cases and widening geographical spread, the 2019 novel coronavirus disease (COVID-19) has been classified as one of the class B infectious diseases but prevented and controlled as class A infectious disease by the National Health Commission of China. The diagnosis and treatment of lung cancer patients have been challenged greatly because of extraordinary public health measures since the lung cancer patients are a high-risk population during the COVID-19 outbreak period. Strict protection for lung cancer patients is needed to avoid infection. Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients. This review will demonstrate how to applicate appropriate and individual management for lung cancer patients to protect them from COVID-19."],"journal":"Zhonghua Zhong Liu Za Zhi","authors":["Yang, L","Xu, H Y","Wang, Y"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32118394","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112152-20200229-00152","keywords":["COVID-19","Diagnostic and therapeutic strategy","Lung neoplasm"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352134334152705,"score":54.68693},{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1663352134282772480,"score":52.353165},{"pmid":32147577,"title":"The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2.","text":["The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2.","J Thorac Oncol","Zhang, Hongyan","Huang, Yihua","Xie, Conghua","32147577"],"journal":"J Thorac Oncol","authors":["Zhang, Hongyan","Huang, Yihua","Xie, Conghua"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32147577","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.jtho.2020.02.025","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352134144360448,"score":46.93279},{"pmid":32245904,"title":"How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere.","text":["How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere.","New cases of the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. A few reports have showed that mortality due to SARS-CoV-2 is higher in elderly patients and other active comorbidities including cancer. To date, no effective treatment has been identified and management for critically ill patients relies on management in intensive care units. Patients with lung cancer are at risk of pulmonary complications from COVID-19. Furthermore, the use of chemotherapy might have a negative impact in patient's outcome. Therefore, the risk/benefit ratio of systemic anticancer treatment (SACT) has to be considered. For each patient, several factors including age and comorbidities, as well as the number of hospital visits for treatment, can influence this risk. Each hospital around the world has issued some internal policy guidelines for oncologists, aiming to limit risks during this difficult time. We hereby propose a tool to support oncologists and physicians in treatment decision for patients with lung cancer. There are several variables to consider, including the extent of the epidemic, the local healthcare structure capacity, the risk of infection to the individual, the status of cancer, patients' comorbidities, age and details of the treatment. Given this heterogeneity, we have based our suggestions bearing in mind some general factors There is not easy, universal solution to oncological care during this crisis and, to complicate matters, the duration of this pandemic is hard to predict. It is important to weigh the impact of each of our decisions in these trying times rather than rely on routine automatisms.","ESMO Open","Banna, Giuseppe","Curioni-Fontecedro, Alessandra","Friedlaender, Alex","Addeo, Alfredo","32245904"],"abstract":["New cases of the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. A few reports have showed that mortality due to SARS-CoV-2 is higher in elderly patients and other active comorbidities including cancer. To date, no effective treatment has been identified and management for critically ill patients relies on management in intensive care units. Patients with lung cancer are at risk of pulmonary complications from COVID-19. Furthermore, the use of chemotherapy might have a negative impact in patient's outcome. Therefore, the risk/benefit ratio of systemic anticancer treatment (SACT) has to be considered. For each patient, several factors including age and comorbidities, as well as the number of hospital visits for treatment, can influence this risk. Each hospital around the world has issued some internal policy guidelines for oncologists, aiming to limit risks during this difficult time. We hereby propose a tool to support oncologists and physicians in treatment decision for patients with lung cancer. There are several variables to consider, including the extent of the epidemic, the local healthcare structure capacity, the risk of infection to the individual, the status of cancer, patients' comorbidities, age and details of the treatment. Given this heterogeneity, we have based our suggestions bearing in mind some general factors There is not easy, universal solution to oncological care during this crisis and, to complicate matters, the duration of this pandemic is hard to predict. It is important to weigh the impact of each of our decisions in these trying times rather than rely on routine automatisms."],"journal":"ESMO Open","authors":["Banna, Giuseppe","Curioni-Fontecedro, Alessandra","Friedlaender, Alex","Addeo, Alfredo"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245904","week":"202014|Mar 30 - Apr 05","doi":"10.1136/esmoopen-2020-000765","keywords":["Editorial"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135868219394,"score":43.674427}]}